Business and Finance

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

The offering will become available in 49 states by next year.

A panel dives into the current and future outlook of healthcare policies.

Session dives into how healthcare policy implementation impacts stakeholders long-term.

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.

The conference’s opening keynote sets the scene for 2025 and the years to come.

The company’s annual edition reveals the latest numbers in the sector, including a rise in average employer-sponsored health insurance premiums for single and family coverage of 24% and 28% respectively.

A deep dive into the future of patient service programs and the value of transparency throughout the process.

How can buyers maximize the value of their acquisitions?

In a final part of his interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, explains the amount of time it takes to see a reduction in annualized drug spend, and offers estimates in terms of percent savings.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, discusses why mitigating the impact of rising costs is imperative, while explaining the benefit of advanced analytics tools.

The company boosts its healthcare logistics services by agreeing to purchase Frigo-Trans and its sister company BPL.

The joint venture aims to disrupt pathological lncRNA interactions with RNA-binding proteins using NextRNA’s platform.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

The partnership creates an integrated solution that also tackles compliance challenges within the sector.

A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.

The collaboration—which is now active until 2031, features a $25 million payment to Evotec for progress made in neurodegenerative disease research.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Balancing innovation focus with optimized decision-making.

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.

The partnership—which features a $150 million investment—is also centered around vaccine development in the respiratory and immunology space.

The acquisition provides Ardian with greater insight into the life science industry.

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

The deal exponentially grows the CDMO’s biopharma capabilities.